In 2002, drug maker GlaxoSmithKline PLC had sent across quality-assurance managers, Cheryl Eckard, to Puerto Rico to aid in cleaning the heap of mess that gathered around its biggest manufacturing plants. U. S. authorities claimed for certain violations, which aimed at contaminated ointment implemented for treating skin infections on children.

Ms. Eckard's journey from North Carolina to the Caribbean now claims that the government is not offering any money to patch up the discussions laid for manufacturing deficiencies.

Ms. Eckard's bounty is tainted to be one of the largest award offered to any single whistleblower in U. S. history.

Other drug firms like Pfizer Inc. and Eli Lilly & Co., have accumulated billions of dollars to settle the impositions. Lawyers state that the publicity has accumulated new heights of settlements and offers a new wave for the would-be whistleblowers, looking up for awards.

Joseph E. B. White, a Philadelphia attorney who represents whistleblowers explains, "The breadth of cases has expanded to include different areas we've never seen before."

Meanwhile, Mr. White believes that the main aim of health-care-fraud cases expansion is apparently because of allegations of manufacturing issues related with the submission of false clinical-trial data to gain a regulatory nod for new drugs.